ERBB2 and breast carcinoma: In line with this, findings from the TBCR026 and PHERGAIN trials underscore the importance of early reduction in the standardized uptake value as a predictive marker for the response to neoadjuvant systemic therapy, particularly when HER2-targeted drugs are involved in the treatment of HER2+ breast cancer [38,39].